Company Focus
Chugai
Latest Chugai News
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Chugai
Pharmaceutical
The European Commission (EC) has approved Balversa (erdafitinib) from US healthcare giant Johnson & Johnson in bladder cancer. 23 August 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has published its final evidence report evaluating the clinical effectiveness and value of Rytelo (imetelstat), raising concerns about the drug's net health benefits and its high cost. 23 August 2024
Biotechnology
China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologics’ Dupert (fulzerasib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy. 22 August 2024
Biotechnology
Stockholm-based biotechnology firm Oblique Therapeutics has announced an expanded research collaboration with US pharma giant Eli Lilly (NYSE: LLY). 22 August 2024
Pharmaceutical
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Biotechnology
BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investors. 22 August 2024
Biotechnology
Chinese biotech start-up TYK Medicines has raised $74 million through an IPO in Hong Kong, according to a public notice. 21 August 2024
Biotechnology
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
Biotechnology
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the biologics license application (BLA) for linvoseltamab.. 21 August 2024
Latest In Brief for Chugai
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
30 October 2024
28 October 2024
26 October 2024
23 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze